Cite
HARVARD Citation
Eggermont, A. et al. (2016). Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB–III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity. European journal of cancer. pp. 111-121. [Online].